The oncolytic virus therapy-based cancer drug developer is based on research at Salk Institute and has raised $77m in its series A round.

The oncolytic virus therapy-based cancer drug developer raised $77m in a GV-backed series A round as it prepares to file an IND application next year.

Ionis Pharmaceuticals and Johnson & Johnson Innovation – JJDC were among the investors in a round that will fund development of Aro's centyrin-RNA conjugate medicines.

The Alphabet, GSK, WuXi AppTec, Johnson & Johnson, Roche and Illumina-backed genetic testing service has now raised over $870m altogether.

The Tokopedia and Barito Pacific-backed last-mile delivery service reportedly raised the series B funding at a $736m valuation.

The Novartis-backed retinal disease drug developer has secured $46.9m of series B capital from investors including Johnson & Johnson Innovation – JJDC.

U-M's retinal disease drug developer has secured $46.9m of series B capital from investors including Mints.

The Legend Holdings-backed molecular diagnostics tool provider will use the $91.6m to help bring its products to market.

Trigo, developer of a frictionless checkout system, raised series B financing from investors including Tesco to push its overall funding to $94m.

Sunshine Insurance Group and existing backer Tencent both took part in a series D round that took the medical management software provider's total funding past $115m.